News

WEF: Sharing Sensitive Health Data in a Federated Data Consortium Model An Eight-Step Guide

August 12th 2020 World Economic Forum has recently developed this report on accessing sensitive health data at scale in order to advance research, innovation and patient outcomes. This paper is part of the Forum’s work to create actionable resources for policy-makers, healthcare professionals and leaders of the Fourth Industrial Revolution to navigate complex and sensitive […]

Read More

Shortening the path to Rare Disease diagnosis by using newborn genetic screening and digital technologies

August 11th 2020 The overall objective of this call topic is to shorten the path to RD diagnosis by using newborn/paediatric (infants during their first weeks of life) genetic screening; and, via application of advanced digital technologies that enable rare disease diagnosis / identification. The latter might require consolidation of existing fragmented efforts. In their […]

Read More

Shortening the path to Rare Disease diagnosis by using newborn genetic screening and digital technologies

August 11th 2020 The overall objective of this call topic is to shorten the path to RD diagnosis by using newborn/paediatric (infants during their first weeks of life) genetic screening; and, via application of advanced digital technologies that enable rare disease diagnosis / identification. The latter might require consolidation of existing fragmented efforts. In their […]

Read More

IMI2 JU Scientific Committee recommendations regarding rare diseases

The Scientific Committee of Innovative Medicine Initiative (IMI), published a very interesting recommendation paper on future research needs regarding rare diseases. IRDiRC has been mentioned as a global consortium in rare disease research that involves stakeholders from Africa, Asia, Australia, North America, and Europe. Click here to download the pdf version of the article.

Read More

IMI2 JU Scientific Committee recommendations regarding rare diseases

The Scientific Committee of Innovative Medicine Initiative (IMI), published a very interesting recommendation paper on future research needs regarding rare diseases. IRDiRC has been mentioned as a global consortium in rare disease research that involves stakeholders from Africa, Asia, Australia, North America, and Europe. Click here to download the pdf version of the article.

Read More

IRDiRC Interdisciplinary Scientific Committee (ISC): NEW Leadership

August 4th 2020 Dr. Philip John (P.J.) Brooks has been elected as new Chair of the Interdisciplinary Scientific Committee (ISC). Dr. Brooks is a Program Director in the NIH National Center for Advancing Translational Sciences (NCATS) Office of Rare Diseases Research (ORDR).  Dr. Brooks received his Ph.D. in neurobiology from the University of North Carolina at Chapel Hill. […]

Read More

IRDiRC Interdisciplinary Scientific Committee (ISC): NEW Leadership

August 4th 2020 Dr. Philip John (P.J.) Brooks has been elected as new Chair of the Interdisciplinary Scientific Committee (ISC). Dr. Brooks is a Program Director in the NIH National Center for Advancing Translational Sciences (NCATS) Office of Rare Diseases Research (ORDR).  Dr. Brooks received his Ph.D. in neurobiology from the University of North Carolina at Chapel Hill. […]

Read More

Academia developing medicines for rare diseases to receive free EMA scientific advice

June 25, 2020 To further encourage the development of treatments for rare diseases, EMA will waive all fees for scientific advice for academia developing orphan medicines.The academic sector plays an important role in the development of innovative medicines. Their scientific research is often at the source of novel methodologies and innovative medicines with a potential to benefit patients with rare diseases.Early […]

Read More

Academia developing medicines for rare diseases to receive free EMA scientific advice

June 25, 2020 To further encourage the development of treatments for rare diseases, EMA will waive all fees for scientific advice for academia developing orphan medicines.The academic sector plays an important role in the development of innovative medicines. Their scientific research is often at the source of novel methodologies and innovative medicines with a potential to benefit patients with rare diseases.Early […]

Read More